BioNTech SE BNTX NASDAQ

BioNTech SE (BNTX) reported total assets of $21.98B and total liabilities of $2.76B for fiscal year 2025, resulting in total equity of $19.22B.

The company held $14.83B in cash and short-term investments. Total debt stood at $267.29M, with net debt of $-7.4B. The Debt-to-Equity (D/E) ratio was 0.01 (conservative).

Current ratio is 7.54, indicating strong short-term liquidity. Interest coverage is -45.7x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (65/100) — Total assets $21.98B and equity $19.22B support the company's competitive scale
• VALUE (94/100) — Debt-to-Equity 0.01 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

KRYS

Krystal Biotech, Inc.

$270.00

+0.97%

PTCT

PTC Therapeutics, Inc.

$73.01

+3.68%

CRSP

CRISPR Therapeutics AG

$56.86

+3.70%

SRPT

Sarepta Therapeutics, Inc.

$22.15

+1.65%

NVAX

Novavax, Inc.

$8.39

+3.45%

IOVA

Iovance Biotherapeutics, Inc.

$3.64

+5.20%

DNA

Ginkgo Bioworks Holdings, Inc.

$7.72

+15.57%